# US 2012/0269856 A1 · Stable immunogenic protein having multiple cysteines molecules process therefor and composition thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269856 A1
- Document ID: US20120269856A1
- Status: Published application
- Kind: A1
- Application number: 13/376,660
- Filed: 2009-07-23
- Published: 2012-10-25
- Earliest claimed: 2009-06-09
- Assignees: Bharat Biotech International Limited
- Inventors: Krishna Murthy Ella; Ganapathy Ravi
- Web page: https://patentgrep.com/patent/US20120269856A1

## CPC

- C07K 14/445: Plasmodium
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61P 33/06: Antimalarials
- A61P 37/04: Immunostimulants
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host E. coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of rPvRII and/or rPfF2 to produce cells in high density; inducing expression rPvRII and/or rPfF2 as inclusion bodies; harvesting the cells and isolating the said inclusion bodies; separating rPvRII and/or rPfF2 from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and/or urea; purifying the protein by subjecting to metal-chelate affinity chromatography; re-folding of the purified rPvRII and/or rPfF2 obtained in step e) with a redox system to recover a high yield of the soluble protein, followed by further purifying the desired protein by removing impurities by subjecting to chromatography. Further the invention discloses formulation comprising rPvRII or rPfF2, preferably being lyophilized using polysaccharides preferably sucrose, lactose, and pharmaceutically acceptable adjuvants such as aluminum hydroxide, aluminum phosphate, CpG nucleotides, non-CpG nucleotides, Montanide ISA-720, MF-59, Mono-phosphoryl Lipid-A (MPL-A) and QS-21.

## Claims

### Claim 1

A stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% when prepared by the process comprising:
a) culturing the host E. coli cells containing a desired recombinant gene construct comprising a codon optimized gene sequence of a protein to produce cells in high density,
b) inducing expression of the target protein as inclusion bodies,
c) harvesting the cells and isolating the said inclusion bodies,
d) separating the protein from inclusion bodies by repeated sequential washing and solubilizing with chaotrophic agents comprising guanidine hydrochloride and/or urea,
e) purifying the protein by subjecting to metal-chelate affinity chromatography,
f) re-folding of the purified protein obtained in step e) with a redox system to recover a high yield of the soluble protein, followed by
g) further purifying the desired protein by removing impurities by subjecting to chromatography.

### Claim 2 (depends on 1)

A protein as claimed in claim 1 is stable for twenty four months at a temperature between 2-8° C. and six months at a room temperature.

### Claim 3 (depends on 1)

A protein as claimed in claim 1 is rPvRII and/or rPfF2.

### Claim 4 (depends on 1)

A method as claimed in claim 1, wherein the repeated sequential washing is effected by washing with buffer.

### Claim 5 (depends on 1)

A method as claimed in claim 1, wherein the buffer used is a low salt buffer consisting of 5-50 mM Tris, 2-25 mM EDTA, 50-100 mM sodium chloride, 1-6M urea, 0.1-1% Triton X-100, pH 6.5-7.5 followed by high salt buffer containing 5-50 mM Tris, pH 6.5-7.5 and 0.5-1M sodium chloride.

### Claim 6 (depends on 1)

A method as claimed in claim 1 wherein the harvesting, separating, isolating and solubilizing is carried out under denaturing conditions.

### Claim 7 (depends on 1)

A method as claimed in claim 1, wherein the refolding is effected employing a buffer containing a detergent-dextrin mixture, a co-solvent and a redox pair.

### Claim 8

A method as claimed in 7, wherein the detergent used is a non-ionic one, preferably Triton X-100 at a concentration of 0.1-1.0 mM, a dextrin, preferably beta-cyclodextrin, L-Arginine as a co-solvent and a redox pair comprising at least one of the following: oxidized and reduced glutathione; L-cysteine-cystamine dihydrochloride, preferably L-cysteine-cystamine dihydrochloride.

### Claim 9

A method as claimed in 7, wherein the refolding buffer further comprising one or more of the amino acids selected from L-cystine, L-cysteine, L-proline and L-lysine.

### Claim 10 (depends on 1)

A method as claimed in claim 1, wherein the re-folded PvRII is further purified by column chromatography to be free from chaotrophic agent, detergents, monomers and multimers.

### Claim 11 (depends on 1)

A stable composition comprising of a protein as claimed in claim 1 wherein the protein is present in the range of 10 μg to 100 μg and pharmaceutically acceptable adjuvants.

### Claim 12 (depends on 1)

A pharmaceutical composition of a protein as claimed in claim 1 where in rPvRII or rPfF2, preferably being lyophilized using at least one of the following: sucrose, lactose, maltose, trehalose, melibiose, mannitol, sorbitol and dextrose, or combinations thereof and in the range of 5 to 10% preferably sucrose or lactose and pharmaceutically acceptable adjuvants.

### Claim 13 (depends on 12)

A pharmaceutical composition as claimed in claim 12, wherein the pharmaceutically acceptable adjuvants used are selected from, but not limited to: aluminum hydroxide, aluminum phosphate, CpG nucleotides, non-CpG nucleotides, Montanide ISA-720, MF-59, Mono-phosphoryl Lipid-A (MPL-A) and QS-21, used either singly or in combinations thereof for use as a vaccine against malarial infections.

### Claim 14 (depends on 1)

A pharmaceutical composition of a protein as claimed in claim 1 is useful as vaccine for immunization by at least one of the following routes of administration: subcutaneous, intra-dermal or parental.
